The Heart Failure Team Heart Failure Care Map First 24 hours.

Slides:



Advertisements
Similar presentations
PRIMA-study main outcome ACC Orlando March 2009 NT-proBNP guided management of chronic heart failure based on an individual target value PRIMA-study Luc.
Advertisements

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
RHP 14 Learning Collaborative July 18, DSRIP Project Overview  Key project areas at Odessa Regional Medical Center Speech Pathology Diabetes Education.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.
Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: BNP-Guided vs Symptom-Guided Heart Failure Therapy:
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Utility of B-type natriuretic peptide in the diagnosis.
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Biomarkers that “guide” therapy
Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy.
The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.
CTC Clinical Strategy and Cost Committee
BNP in Heart Failure Azam Hadi MD 9/17/2018.
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
CLINICAL DILEMMAS IN HEART FAILURE:
Hospitalizations and Healthcare Costs Need for Reduction in Hospitalizations of Patients With HF
Stephen W. Waldo et al. JACC 2008;51:
Acute Heart Failure.
Hyperkalemia in the Hospital: Collaboration to Improve Transitions of Care.
Cardiac Biomarkers.
Biomarkers in Heart Failure
Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.
Treatment of Complicated Intra-abdominal Infections
Cost Effectiveness and Optimal Outcomes in HF
Clyde W. Yancy et al. JACC 2017;70:
Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy
nAMD: Switching Therapies - what you need to know
Heart Failure Management Coordinated Care Approaches
Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.
Heart Failure Prevention: Mission Impossible?
Tailoring Hemophilia Prophylaxis Therapy
Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.
Preventing Heart Failure Readmission and Progression
Antithrombotic Protection in CAD and HF
Biomarker-Guided HF Therapy: Is It Cost-Effective?
G. Michael Felker et al. JCHF 2014;2:
Editorial Heart Failure Clinics
Overcoming Clinical Inertia
Updates in Heart Failure:
Revisiting the Pharmacoeconomics of HF
Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Challenging the Myths in Heart Failure With Reduced Ejection Fraction
Heart Failure. Enhancing Myosin Activation and Cardiac Contractility: Implications for Heart Failure.
ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.
Principal recommendations
TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.
CAD and HF Often Coexist
Program Goals Background: Anticoagulation in Patients With VTE.
Improving Adherence to Antiplatelet Therapy After an ACS Event
Post-Heart Failure Mortality
Total Outpatient Visits
Baseline Characteristics by Baseline N-BNP Level
Contemporary Considerations in Biomarker-Guided Therapy
Emilce Trucco et al. JACEP 2018;j.jacep
HF-Related Hospitalization and Readmissions
Our Community Where is …?.
MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).
When we compared cardiac volumes (ED and ES) between those with high BNP levels (BNP >400 pg/mL) and low BNP (
Pulmonary Arterial Hypertension and Hospitalizations
The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.
In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?
Recurrence of HF hospitalization Total-time approach
Cohort and Community Surveillance Components
Top Tips in Evidence-Based Care for HFrEF
Key Data on Improving Outcomes in HF Patients
Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.
Diagnosing HFpEF: What Every Cardiologist Needs to Know
Presentation transcript:

The Heart Failure Team

Heart Failure Care Map First 24 hours

Heart Failure Care Map Next 24 hours

National Hospital Discharge Survey 1980-1984 and 2000-2004

Hospital-to-Community A Team Approach

Utilization of Natriuretic Peptide Measurements in Heart Failure

STARS-BNP BNP-guided HF Therapy

STARS-BNP Hospital Stays

Benefit of Natriuretic Peptide-Guided Therapy

PROTECT ProBNP Outpatient-Tailored Chronic Heart Failure Therapy

PROTECT Guided Therapy and Change in Echocardiographic Parameters

GUIDE-IT

Natriuretic Peptide Guided Therapy What to Do Next When Levels Remain High

Natriuretic Peptide-guided Therapy Meta-analysis of 12 Randomized Trials

Natriuretic Peptide-Guided Therapy Unanswered Questions

Abbreviations

Abbreviations (cont)

References

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.